Cooper Co, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Saxon from Needham maintained a Buy rating on the stock and has a $99.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
David Saxon has given his Buy rating due to a combination of factors tied to Cooper Co.’s competitive positioning against new contraceptive offerings. He notes that Organon’s planned launch of Miudella, a non-hormonal IUD, could increase competition for Cooper’s Paragard franchise, given Organon’s broader contraceptive portfolio and commercial reach.
However, he emphasizes that Miudella’s shorter three‑year duration versus Paragard’s ten‑year label, along with its nitinol frame that constrains use in patients with nickel sensitivity, should limit its direct substitution risk. As a result, Saxon appears to view the incremental competitive headwind as manageable, supporting a continued constructive stance on Cooper Co. shares.